Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT  by Sorror, M.L. et al.
Intravenous (IV) busulfan (BU) gives more predictable exposure
than the oral form and is easier to administer once daily than the
conventional four times daily schedule. Fludarabine is immuno-
suppressive, antileukaemic and perhaps better tolerated than cy-
clophosphamide. Low-dose pretransplant ATG appears to reduce
morbidity and mortality of graft-versus-host disease (GVHD). A
conditioning regimen incorporating these agents appears well tol-
erated and adding a low dose of total body irradiation (TBI) does
not seem to increase non-relapse mortality. This regimen was
given to a total of 64 acute leukemia patients (pts) aged 18-63
(median 40) years of whom 28 (44%) had ALL or lymphoblastic
lymphoma (n  2) in CR1 (n  22) or CR2 (n  6), and 36 (66%)
had AML (25 CR1, 11 CR2). Donors were matched siblings
(MRD) for 31 (48%) and alternate donors (AD, 28 unrelated and
5 mismatched related) for 33 (52%). Cell source was blood in all
MRD and 26 (76%) AD pts. All pts received ﬂudarabine 50 mg/m2
on days 6 to 2 and IV BU (Busulfex, ESP Pharma) at a
“myeloablative” dose of 3.2 mg/kg daily days 5 to 2 inclusive
and TBI 200 cGy  2 on day 1 or 0. Prophylaxis for GVHD was
cyclosporine A, “short course” methotrexate with folinic acid and
Thymoglobulin (Genzyme) 4.5 mg/kg in divided doses over 3
consecutive days pretransplant ﬁnishing day 0. Follow-up of sur-
vivors is 3-64 months, median 20. After MRD and AD transplants
the incidence of acute GVHD grade II-IV was 11  6% vs 35 
9% (P  .047), acute GVHD grade III-IV was 0% vs 10  6%
(P  .09) and chronic GVHD was 46  10% vs 73  9% (P  ns)
respectively. There were 3 transplant-related deaths, only in ALL
patients, one each from acute GVHD, pneumonitis and PTLD
giving an overall TRM of 5  3%. Of 6 relapsing pts with ALL 4
are in a further remission after a second myeloablative transplant
(3) or chemotherapy and DLI (1), all have chronic GVHD. Four
AML pts died from relapse. Projected 2-year disease-free survival
and survival respectively is 72  9% and 80  8% for ALL, 87 
6% and 87  6% for AML. For the combined group the corre-
sponding ﬁgures are 80  8% and 89  6% for MRD and 78 
8% and 78  8% for AD transplants respectively (P  ns). This
regimen appears relatively well tolerated and gives equivalent ﬁnal
outcomes from MRD and AD. If these results can be conﬁrmed the
combination deserves study in children with acute leukemia in
whom the toxicity of higher doses of TBI could be avoided.
16
COMPARISON OF METHOTREXATE- VERSUS SIROLIMUS-CONTAINING
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS REGIMENS AFTER MY-
ELOABLATIVE STEM CELL TRANSPLANTATION
Saito, A.M.1, Cutler, C.1, Zahrieh, D.2, Soiffer, R.J.1, Ho, V.T.1,
Alyea, E.P.1, Antin, J.H.1, Lee, S.J.1 1Department of Medical Oncology,
Dana-Farber Cancer Institute and Brigham and Women’s Hospital,
Boston, MA; 2Department of Biostatistical Science, Dana-Farber Cancer
Institute, Boston, MA.
Background: Graft-versus-host disease (GvHD) is a serious
complication after allogeneic hematopoietic stem cell transplanta-
tion (HSCT). Methotrexate in combination with a calcineurin
inhibitor (CM) is considered standard GvHD prophylaxis. Studies
suggest that sirolimus in combination with a calcineurin inhibitor
(SC) is effective in preventing GvHD and minimizing transplant-
related morbidity and mortality. Method: A total of 159 patients
with hematological diseases underwent myeloablative HLA-
matched HSCT with either CM (n 97) or SC (n 62) as GvHD
prophylaxis at the Dana-Farber Cancer Institute between June
2000 and December 2004 using Cytoxan and TBI conditioning.
Inpatient costs for the ﬁrst transplant year of 94 CM and 47 SC
recipients were obtained. We compared inpatient costs and clinical
outcomes for the ﬁrst transplant year between the two different
GvHD prophylaxis groups by use of univariate and multivariate
analyses. Results: CM recipients were more likely to have unre-
lated donors, BM grafts, and to be transplanted in earlier years than
SC recipients. In univariate analysis, the SC regimen was associ-
ated with faster engraftment (13 days vs 17 days, P  .01), less
grade II to IV acute GvHD (18% vs 37%, P .01) and better DFS
(71% vs 52%, P  .01) and OS (72% vs 53%, P  .01). Days of
initial hospitalization and costs within the ﬁrst year were lower for
SC in the univariate analysis (27 days vs 33 days, P  .01, $101697
vs $110081, P  .03, respectively) but not in the multivariate
analysis (ratio (CM vs SC) 0.99, P  .91, ratio 1.14, P  .30,
respectively). Use of an unrelated donor was the only signiﬁcant
predictor of high costs considering baseline patient characteristics.
In contrast, grade II to IV aGvHD, late engraftment, and in-
hospital death were the signiﬁcant factors associated with high
costs considering both baseline patient characteristics and post-
transplant events. Conclusion: Both OS and DFS in the SC group
were higher in the multivariate analysis, probably due to early
engraftment and reduced incidence of grade II to IV aGvHD seen
in SC group. However, we could not detect the impact of GvHD
prophylaxis on inpatient costs for the ﬁrst transplant year. The SC
regimen is a promising alternative to CM and larger multi-center
randomized trial is planned through the NIH-funded Clinical
Trials Network.
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VALIDATION OF THE PREDICTIVE POWER OF THE HEMATOPOIETIC
CELL TRANSPLANTATION-COMORBIDITY INDEX (HCT-CI) FOR NON-
RELAPSE MORTALITY (NRM) AND SURVIVAL AFTER ALLOGENEIC HCT
Sorror, M.L.1, Giralt, S.2, Sandmaier, B.1,3, Maris, M.1,3,
Maloney, D.1,3, Deeg, H.J.1,3, Appelbaum, F.1,3, Storer, B.1,3,
Storb, R.1,3 1Fred Hutchinson Cancer Research Center; 2M. D. Anderson
Cancer Center, Houston, TX; 3University of Washington, Seattle, WA.
The HCT-CI proved to be a sensitive tool to capture pretrans-
plant comorbidities among patients (pts) given allogeneic HCT at
FHCRC (Blood 2005;106:2912). We sought to validate the effec-
tiveness of the HCT-CI in predicting NRM and survival at an-
other institution (MDACC) and compare its performance to those
of other comorbidity indices. For this purpose, pretransplant co-
morbidities were assessed in pts with acute myeloid leukemia in
ﬁrst remission from FHCRC (n  137) and MDACC (n  70) by
two independent investigators. Comorbidities were scored using
HCT-CI, Charlson comorbidity index (CCI), and the adult co-
morbidity evaluation (ACE-27, a recent modiﬁcation of the
Kaplan-Feinstein Index). Conditioning included myeloablative
(78% and 69% of FHCRC and MDACC pts, respectively) or
reduced intensity regimens. Donor grafts were from related (66%
and 86% of FHCRC and MDACC pts, respectively) or unrelated
donors. Stem cell source was marrow (28% and 60% of FHCRC
and MDACC pts, respectively) or G-PBMC. Among the 207 pts,
35%, 29%, and 36%, respectively, had HCT-CI scores of 0 vs 1-2
vs 3; 83%, 9%, and 8%, respectively, had CCI scores of 0 vs 1 vs
2; and 56%, 28%, and 16%, respectively, had ACE-27 scores of
0 vs 1 vs2. HCT-CI scores of 1-2 and3 were found in 33% and
25% FHCRC pts and 20% and 59% MDACC pts. Cumulative
incidences of 2-year NRM were 5%, 7%, and 24%, respectively,
among FHCRC pts with HCT-CI scores of 0 vs 1-2 vs3 and 7%,
14%, and 31% among their MDACC counterparts. Unadjusted
hazard ratios (HR) for NRM were 1.11 and 4.3 for HCT-CI scores
of 1-2 and 3 among FHCRC pts compared to 2.41 and 5.72
among MDACC pts. Similarly, HR for worse survival were 2.47
and 6.21 for HCT-CI scores of 1-2 and 3 among FHCRC pts
compared to 2.18 and 2.73 among MDACC pts. In multivariable
regression analyses, HCT-CI scores showed the highest prediction
for NRM (HR 5.13, P  .001) and worse survival (HR 4.96, P 
.0001) compared to CCI scores (P  .2 and .05, respectively) and
ACE-27 scores (P .03 and .002, respectively). These results were
further validated separately at each institution (Table 1), where
higher HCT-CI scores showed the highest HR predicting of NRM
and worse survival among FHCRC and MDACC pts compared to
other risk factors. Results conﬁrm the ability of HCT-CI to predict
post-HCT outcomes. The HCT-CI identiﬁed more pts with co-
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morbidities than either CCI or ACE-27. The HCT-CI should be
used prospectively to stratify pts in future clinical trials (Table 1).
Table 1. Multivariable Cox Regression Models
Risk factor
FHCRC Pts (n  137) MDACC Pts (n  70)
HR (95% CI)
for Higher
NRM
HR (95% CI)
for Worse
Survival
HR (95% CI)
for Higher
NRM
HR (95% CI)
for Worse
Survival
HCT-CI
scores
0 1.0 1.0 1.0 1.0
1–2 0.95
(0.2–4.4)
2.32
(0.9–6.0)
2.41
(0.2–27)
2.34
(0.7–8.0)
>3 6.35
(1.7–24)
8.88
(3.5–22)
5.72
(0.7–44)
2.95
(1.0–8.9)
Donor Related 1.0 1.0 1.0 1.0
Unrelated 1.94
(0.6–6.7)
3.05
(1.4–6.5)
0.44
(0.1–3.6)
1.45
(0.6–3.8)
Stem cell
source
G-PBMC 1.0 1.0 1.0 1.0
Marrow 5.49
(1.5–21)
3.31
(1.5–7.4)
1.48
(0.5–4.8)
0.94
(0.4–2.1)
Conditioning Myeloablative 1.0 1.0 1.0 1.0
Reduced
intensity
1.04
(0.2–5.7)
0.48
(0.2–1.4)
1.99
(0.5–8.0)
1.29
(0.5–3.4)
Age <50 1.0 1.0 1.0 1.0
>50 1.54
(0.4–6.2)
2.33
(1.0–5.2)
0.62
(0.2–2.5)
0.70
(0.3–1.9)
FHCRC indicates Fred Hutchinson Cancer Research Center;
MDACC, M. D. Anderson Cancer Center; HCT-CI, hemato-
poietic cell transplantation-speciﬁc comorbidity index; and G-
PBMC, G-CSF mobilized peripheral blood mononuclear cells.
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HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM UNRELATED
UMBILICAL CORD BLOOD IN ELDERLY PATIENTS (>54 YEARS): OLDER
AGE IS NO LONGER A CONTRAINDICATION WHEN USING REDUCED-
INTENSITY CONDITIONING
Uchida, N.1, Wake, A.1, Takagi, S.1, Kato, D.1, Kawano, T.1,
Matsuhashi, Y.1, Kusumi, E.1, Matsumura, T.1, Masuoka, K.1,
Miyakoshi, S.1, Taniguchi, S.1 1Toranomon Hospital, Minato-ku, To-
kyo, Japan.
Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive approach for patients (pts) with hematological malignancies.
However, elderly pts have often been deterred from this approach
due to high risks of treatment-related complications and less
chance of getting suitable donors. Umbilical cord blood transplan-
tation with reduced-intensity conditioning (RI-UCBT) allowed
extension of allogeneic SCT to a wider pt population including the
elderly. However, there are only limited data on the feasibility and
outcome in elderly pts. In this study, we report our experience with
63 pts aged 55 years old and older having RI-UCBT. The median
age was 62 years (range, 55-79). Thirty-six pts were over 60,
including 6 pts over 70. Diagnoses included AML (n  20), ALL
(n  7), MDS (n  8), ATL (n  14), CML (n  4), NHL (n 
7), MM (n  1), and SAA (n  2). The preparative regimen
consisted of ﬂudarabine (125 mg/m2) combined with melphalan
(80 mg/m2) and 4 Gy total body irradiation for most of the patients
(n  60). Either cyclosporine alone (n  37) or tacrolimus alone
(n  26) were employed as GVHD prophylaxis. Forty-eight pts
engrafted with a median of 19 days (range, 11-53). Five pts died
prior to engraftment. With a median follow-up of 116 days (range,
11-1092), 20 pts are alive and 43 have died; 32 of treatment-related
causes (16 of infection, 7 of GVHD, 4 of IP, 2 of TMA, and 3 of
others) and 12 of relapse. The probabilities of overall survival at
2-year after SCT were 32.8% (95 CI, 15-51%). Acute GVHD
occurred in 31 pts, 22 of those were in grade II-IV. Pts aged 62 and
older had an OS of only 16.1%, whereas pts younger than 62 years
old had an OS of 48.5% (P  .008). There was a tendencies for pts
in standard risk group (acute leukemia in remission, CML AP,
SAA, and untreated MDS) to have better OS of 54.5% than those
in high risk group (all the rest, OS  28.3%, P  .06), and for pts
who had tacrolimus as GVHD prophylaxis (OS  46.2%) than
those with cyclosporine (OS  23.7%, P  .09), although the
differences were not statistically signiﬁcant. When the pts aged 62
and older were analysed, tacrolimus group (n  11) tended to have
a greater chance to survive (OS36.4%) than cyclosporine group
(n 11, OS5.0%). In conclusion, RI-UCBT is feasible in elderly
pts. Even within this group of pts, older age (62 years and older) is
still an unfavorable factor for survival. Tacrolimus as GVHD
prophylaxis may, however, have a potential to improve outcome for
those in higher age range.
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NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR SYSTEMIC LUPUS ERYTHEMATOSUS
Statkute, L.1, Oyama, Y.1, Verda, L.1, Barr, W.G.2, Rosa, R.3,
Schroeder, J.2, Krosnjar, N.1, Quigley, K.1, Yaung, K.1, Villa, M.1,
Takahashi, M.1, Burt, R.K.1 1Division of Immunotherapy, Department
of Medicine, Northwestern University Feinberg School of Medicine,
Chicago, IL; 2Division of Rheumatology, Department of Medicine,
Northwestern University Feinberg School of Medicine, Chicago, IL;
3Division of Nephrology, Department of Medicine, Northwestern Uni-
versity Feinberg School of Medicine, Chicago, IL.
Patients with systemic lupus erythematosus (SLE) usually re-
spond well to immunosuppressive medications. However, there
is a subset of refractory SLE patients for whom current strate-
gies are insufﬁcient to control disease. Here we report results of
autologous non-myeloablative hematopoietic stem cell trans-
plantation (HSCT) single arm trial performed at Northwestern
University Feinberg School of Medicine between February 1997
and January 2005 which involved 50 patients with SLE refrac-
tory to standard immune suppressive therapies and either organ-
or life-threatening visceral involvement. The primary endpoint
was survival, both overall survival and disease free survival.
Secondary endpoints include systemic lupus erythematosus dis-
ease activity index (SLEDAI), serology (ANA and anti-ds
DNA), complement (C3 and C4), and changes in renal and
pulmonary organ function assessed pre-treatment and at 6, 12
months and then yearly for 5 years. Peripheral blood stem cells
were mobilized with intravenous (IV) cyclophosphamide (CY)
(2.0 g/m2) and subcutaneous G-CSF (5 g/kg/day). The graft
was enriched ex vivo by CD34 immunoselection. Conditioning
regimen consisted of IV CY (200 mg/kg) and equine anti-
thymocyte globulin (90 mg/kg). Fifty patients were enrolled and
underwent stem cell mobilization. Two patients died after mo-
bilization, one from disseminated mucormycosis and another
from active lupus after postponing the transplant for 4 months.
Forty-eight patients underwent lupus non-myeloablative HSCT
with no treatment related mortality. By intention to treat, treat-
ment related mortality was 2% (1/50). With a mean follow-up of
29 months (range 6 month to 7.5 years), overall survival was
84%, and probability of disease free survival at 5 years post
transplant was 50%. SLEDAI, ANA, anti-ds DNA, comple-
ment, and lung diffusion capacity of carbon monoxide adjusted
for hemoglobin (DLCOadj) signiﬁcantly statistically (P  .05)
improved. Renal function assessed by creatinine and creatinine
clearance remained stable overall. Results of our trial suggest
that in patients with treatment refractory SLE autologous non-
myeloablative HSCT markedly ameliorates disease activity and
so confers long term disease remission, improvement in sero-
logic markers, and either stabilization or reversal of organ dys-
function.
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